X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Core Perspective - The company aims to be a leader in developing new therapies for patients with rare blood disorders, specifically focusing on mavorixafor for chronic neutropenia [2]. Group 1: Company Strategy - The management team has been in place for about 6 months, concentrating efforts on achieving the company's goals [1]. - Significant cost reductions and headcount decreases have been implemented to streamline operations [3]. - The primary focus is on successfully completing the Phase III trial to bring the new indication to patients [3].